Eliot A. Brinton, MD

Articles by Eliot A. Brinton, MD

Closing Thoughts on ASCVD Management

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 12th 2026

Experts reveal how risk assessment, LDL-C targets, and smarter follow-up boost adherence—turning guidelines into real cardiovascular prevention.

Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 5th 2026

Learn how clinicians reach ultra-low LDL targets in high-risk patients using ezetimibe, PCSK9s, and smarter insurance documentation.

Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 5th 2026

Why patients quit cholesterol therapy—and how LDL checkups, reminders, and longer-acting injectables improve lifelong medication adherence.

Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 29th 2026

Compare statins, ezetimibe, bempedoic acid and PCSK9 inhibitors for side effects, dosing preferences, and shared decision-making tips.

Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 29th 2026

Compare statin side effects with ezetimibe, bempedoic acid and PCSK9 inhibitors, plus practical dosing tips and shared decision-making.

Advancing ASCVD Management with PCSK9 Inhibitors

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 22nd 2026

Explore where ezetimibe and bempedoic acid fit for statin‑reluctant patients, lowering LDL with proven outcomes and diabetes benefits.

The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 22nd 2026

Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 15th 2026

See how coronary calcium images and risk graphs boost engagement, drive LDL-lowering choices, and help more patients reach cholesterol goals.

Driving Patient Engagement in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 15th 2026

Navigating Combination Therapy and Access Challenges in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 8th 2026

Learn how clinicians personalize LDL-lowering therapy, address statin fears, and choose pills or injections to hit cholesterol goals despite cost barriers.

Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 8th 2026

Clinicians shift from “hyper” labels to atherosclerosis risk, using diabetes markers and LDL targets to prevent heart attack and stroke.

Eliot A. Brinton, MD, outlines the continued unmet needs for patients with familial chylomicronemia syndrome (FCS).

Latest Updated Articles

Finding a Path Forward: The Continued Unmet Medical Need in FCS
January 30th 2019

Eliot A. Brinton, MD

Articles by Eliot A. Brinton, MD

Closing Thoughts on ASCVD Management

Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD

Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD

Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

Advancing ASCVD Management with PCSK9 Inhibitors

The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

Driving Patient Engagement in ASCVD

Navigating Combination Therapy and Access Challenges in ASCVD

Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD

Examining the 2026 ACC/AHA Dyslipidemia Guidelines for ASCVD

ASCVD Risk Assessment and LDL-C Management

Finding a Path Forward: The Continued Unmet Medical Need in FCS

Latest Updated Articles

Trending on HCPLive

Prevalence and Recognition of Hypercortisolism

Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes

Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH

Distinguishing CSU From Chronic Inducible Urticaria Subtypes

Diagnosing the Hallmark Signs and Symptoms of CSU